Titan Pharmaceuticals Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
Titan Pharmaceuticals has a total shareholder equity of $4.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $4.4M and $356.0K respectively.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
US$0
Schuld
Rente dekkingsratio | n/a |
Contant | US$4.09m |
Aandelen | US$3.99m |
Totaal verplichtingen | US$356.00k |
Totaal activa | US$4.35m |
Recente financiële gezondheidsupdates
Recent updates
Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?
Jul 10Titan Pharma regains Nasdaq listing compliance
Dec 16Titan Pharmaceuticals announces 1-for-30 reverse stock split
Nov 30Titan Pharmaceuticals EPS misses by $0.01, beats on revenue
Nov 16Titan Pharma closes debt settlement and JT-09 acquisition
Nov 02Titan Pharma to raise $8M in stock offering
Oct 28Analyse van de financiële positie
Kortlopende schulden: TTNP's short term assets ($4.4M) exceed its short term liabilities ($356.0K).
Langlopende schulden: TTNP has no long term liabilities.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: TTNP is debt free.
Schuld verminderen: TTNP currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: TTNP has less than a year of cash runway based on its current free cash flow.
Voorspelling contante baan: TTNP has less than a year of cash runway if free cash flow continues to grow at historical rates of 12.3% each year.